CN102770450B - 因子viii融合蛋白 - Google Patents

因子viii融合蛋白 Download PDF

Info

Publication number
CN102770450B
CN102770450B CN201180009864.4A CN201180009864A CN102770450B CN 102770450 B CN102770450 B CN 102770450B CN 201180009864 A CN201180009864 A CN 201180009864A CN 102770450 B CN102770450 B CN 102770450B
Authority
CN
China
Prior art keywords
molecule
fviii
fusion
domain
factor viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180009864.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102770450A (zh
Inventor
G.博尔特
K.克杰加尔德
P.L.诺尔比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to CN201510524808.4A priority Critical patent/CN105153313A/zh
Publication of CN102770450A publication Critical patent/CN102770450A/zh
Application granted granted Critical
Publication of CN102770450B publication Critical patent/CN102770450B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201180009864.4A 2010-02-16 2011-02-10 因子viii融合蛋白 Expired - Fee Related CN102770450B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510524808.4A CN105153313A (zh) 2010-02-16 2011-02-10 因子viii融合蛋白

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10153715 2010-02-16
EP10153715.7 2010-02-16
US30617710P 2010-02-19 2010-02-19
US61/306177 2010-02-19
PCT/EP2011/051959 WO2011101284A1 (en) 2010-02-16 2011-02-10 Factor viii fusion protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510524808.4A Division CN105153313A (zh) 2010-02-16 2011-02-10 因子viii融合蛋白

Publications (2)

Publication Number Publication Date
CN102770450A CN102770450A (zh) 2012-11-07
CN102770450B true CN102770450B (zh) 2015-12-02

Family

ID=42244627

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180009864.4A Expired - Fee Related CN102770450B (zh) 2010-02-16 2011-02-10 因子viii融合蛋白
CN201510524808.4A Withdrawn CN105153313A (zh) 2010-02-16 2011-02-10 因子viii融合蛋白

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510524808.4A Withdrawn CN105153313A (zh) 2010-02-16 2011-02-10 因子viii融合蛋白

Country Status (5)

Country Link
US (2) US9493543B2 (enExample)
EP (2) EP2977055A1 (enExample)
JP (3) JP2013519699A (enExample)
CN (2) CN102770450B (enExample)
WO (1) WO2011101284A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
US20130040888A1 (en) * 2010-02-16 2013-02-14 Novo Nordisk A/S Factor VIII Molecules With Reduced VWF Binding
RS59670B1 (sr) * 2012-01-12 2020-01-31 Bioverativ Therapeutics Inc Himerni polipeptidi faktora viii i njihove upotrebe
DK3564260T5 (da) 2012-02-15 2024-09-02 Bioverativ Therapeutics Inc Faktor viii-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
EA201491388A1 (ru) * 2012-02-15 2015-01-30 Байоджен Айдек Ма Инк. Рекомбинантные белки фактора viii
WO2013083858A1 (en) 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
WO2013160005A1 (en) 2012-04-24 2013-10-31 Novo Nordisk A/S Pharmaceutical composition suitable for treatment of haemophilia
CN104661674A (zh) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
WO2014176311A1 (en) 2013-04-23 2014-10-30 President And Fellows Of Harvard College Genetic reprogramming of bacterial biofilms
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
PL3041513T3 (pl) 2013-09-08 2021-01-25 Kodiak Sciences Inc. Obojnaczojonowe polimerowe koniugaty czynnika viii
CN114736305B (zh) 2014-01-10 2023-05-05 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
PL3177317T3 (pl) 2014-08-04 2020-07-27 Csl Limited Formulacja czynnika viii
KR102210104B1 (ko) 2014-10-17 2021-02-01 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
JP6916524B2 (ja) 2015-04-06 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 機能的タンパク質配列をディスプレイする生合成アミロイドに基づく材料
WO2016198521A1 (en) * 2015-06-10 2016-12-15 Novo Nordisk A/S Fviii fusion proteins
CN104926946B (zh) * 2015-07-13 2021-09-17 中国科学院广州生物医药与健康研究院 具有延长体内半衰期的adamts13-mdtcs融合蛋白及其应用
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
KR20180031775A (ko) 2015-08-12 2018-03-28 셀 머신스, 인크. 긴 반감기 응집 복합체와 관련된 방법 및 조성물
GB201520021D0 (en) * 2015-11-13 2015-12-30 Asterion Ltd Fusion polypeptide
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
US11098133B2 (en) 2016-05-19 2021-08-24 President And Fellows Of Harvard College Methods of making gels and films using curli nanofibers
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
IL308416B2 (en) 2016-12-02 2025-08-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
CN108623695B (zh) * 2017-03-24 2022-03-15 中国科学院过程工程研究所 一种白蛋白结合肽-人睫状神经营养因子融合蛋白及其制备方法和应用
US11584790B2 (en) 2017-04-14 2023-02-21 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
GB201706781D0 (en) 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CN113166271A (zh) * 2018-05-18 2021-07-23 郑州晟斯生物科技有限公司 具有延长半衰期的融合多肽缀合物
WO2019219049A1 (zh) * 2018-05-18 2019-11-21 北京辅仁瑞辉生物医药研究院有限公司 改进的fviii融合蛋白及其应用
MA52630B1 (fr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Procédés de traitement de l'hémophilie a
CN113105562B (zh) * 2018-09-26 2023-12-01 安源医药科技（上海）有限公司 突变型单链人凝血因子viii在制备融合蛋白中的应用
US20220389082A1 (en) 2019-07-04 2022-12-08 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
AU2020342349A1 (en) * 2019-09-02 2022-03-03 Biotest Ag Factor VIII protein with increased half-life
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
JP7680442B2 (ja) 2019-11-11 2025-05-20 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド
KR20220130692A (ko) * 2020-01-20 2022-09-27 우시 바이올로직스 아일랜드 리미티드 친화성 크로마토그래피를 위한 신규한 세척 완충제 용액
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
AU2021347581A1 (en) * 2020-09-23 2023-05-18 Ablevia Biotech Gmbh Compound for the prevention or treatment of autoantibody-mediated conditions
JP2025521136A (ja) * 2022-05-25 2025-07-08 チアンスー ジェンサイエンス インコーポレイテッド 半減期が延長されたｆｖｉｉｉ融合タンパク質コンジュゲート及びその応用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077616A1 (en) * 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
CN101379077A (zh) * 2005-12-07 2009-03-04 夏洛特·豪泽 因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0317641B1 (en) 1987-05-29 1993-03-17 Sagami Chemical Research Center Fused protein containing lymphotoxin
AU2645588A (en) 1987-12-04 1989-06-15 Scripps Clinic And Research Foundation The von willebrand factor binding domain of factor viii
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US6939677B1 (en) 1990-11-01 2005-09-06 Cancer Research Fund Of Contra Costa Antibody with 46 kdalton HMFG antigen binding specificity, immunoassay kit and diagnostic method
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6524572B1 (en) 2000-06-26 2003-02-25 Rainbow Therapeutic Company Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
AU2004204817C1 (en) 2003-01-13 2011-01-20 Macrogenics, Inc. Soluble FcyR fusion proteins and methods of use thereof
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US20070106066A1 (en) 2003-10-28 2007-05-10 Alexander Cherkasky Cherkasky fusion proteins containing antibody-, antigen- and microtubule-binding regions and immune response-triggering regions
WO2005113584A1 (en) 2004-04-29 2005-12-01 Board Of Regents, University Of Texas System Methods and compositions comprising protein l immunoglobulin binding domains for cell-specific targeting
MX2007011801A (es) 2005-03-24 2008-02-19 Neose Technologies Inc Expresion de glicosiltransferasas eucarioticas activas, solubles en organismos procarioticos.
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US20090053790A1 (en) 2006-01-31 2009-02-26 Ishihara Sangyo Kaisha, Ltd. Polypeptide Having Affinity for Envelope Virus Constituent and Use Thereof in Transferring Substance Into Cell
JP5570809B2 (ja) 2006-09-01 2014-08-13 ノボ ノルディスク ヘルス ケア アーゲー 修飾タンパク質
EP2097449A1 (en) 2006-12-05 2009-09-09 Ablynx N.V. Peptides capable of binding to serum proteins
EP2124994A2 (en) * 2007-01-23 2009-12-02 Zymogenetics, Inc. Soluble fc gamma r1a for reducing inflammation
US8043621B2 (en) 2007-05-10 2011-10-25 Ramot At Tel Aviv University Ltd. Recombinant fusion protein and polynucleotide construct for immunotoxin production
WO2009053368A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
RU2573587C2 (ru) * 2008-02-27 2016-01-20 Ново Нордиск А/С Конъюгированные молекулы фактора viii
RU2528855C2 (ru) * 2008-06-24 2014-09-20 Цсл Беринг Гмбх Модифицированный фактор виллебранда с удлиненным полупериодом существования in vivo, его применения и способы получения

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101379077A (zh) * 2005-12-07 2009-03-04 夏洛特·豪泽 因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体
WO2008077616A1 (en) * 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Factor VIII-Fc Fusion Protein Shows Extended Half-Life and Hemostatic Activity in Hemophilia A Dogs;Jennifer A Dumon et al;《BLOOD》;20091130;第114卷(第22期);摘要 *

Also Published As

Publication number Publication date
WO2011101284A1 (en) 2011-08-25
JP2016084365A (ja) 2016-05-19
CN102770450A (zh) 2012-11-07
CN105153313A (zh) 2015-12-16
US20130040889A1 (en) 2013-02-14
EP2536754A1 (en) 2012-12-26
JP2013519699A (ja) 2013-05-30
US9493543B2 (en) 2016-11-15
US20170015729A1 (en) 2017-01-19
JP6185097B2 (ja) 2017-08-23
EP2977055A1 (en) 2016-01-27
JP2017190342A (ja) 2017-10-19

Similar Documents

Publication Publication Date Title
CN102770450B (zh) 因子viii融合蛋白
US11472863B2 (en) Human coagulation factor IX (FIX) fusion protein, preparation method therefor, and use thereof
KR102276157B1 (ko) 고글리코실화 인간 혈액응고인자 viii 융합 단백질 및 그 제조방법과 용도
CN102770449B (zh) 具有降低的vwf结合的因子viii分子
CN103739712B (zh) 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
US20160264645A1 (en) Stabilized Factor VIII Variants
CN112673026B (zh) 突变型单链人凝血因子viii融合蛋白及其制备方法与用途
CN106279436B (zh) 活化的人凝血因子vii融合蛋白及其制备方法与用途
HK40051475A (en) Fusion protein of mutated single-chain human coagulation factor viii, preparation method therefor, and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151202

Termination date: 20180210